Figitumumab

Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]

Figitumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF-1 receptor
Clinical data
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6462H9948N1736O2020S54
Molar mass146008.04 g·mol−1
 NY (what is this?)  (verify)

This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]

Anti-cancer mechanism

See Insulin-like growth factor 1 receptor role in cancer.

Clinical trials

The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]

It was to have been included in the I-SPY2 breast cancer trial.[8]

References
  1. Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
  2. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. (March 2010). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer Chemotherapy and Pharmacology. 65 (4): 765–73. doi:10.1007/s00280-009-1083-9. PMC 2875253. PMID 19649631.
  3. Gualberto A, Karp DD (July 2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer. 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947.
  4. "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.
  5. Krauskopf L (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
  6. Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
  7. Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
  8. "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.